CJC-1295 vs Sermorelin — Detailed Comparison
CJC-1295 and sermorelin are both growth hormone-releasing hormone (GHRH) analogues, but they differ significantly in pharmacokinetics, potency, and clinical application. CJC-1295 is a modified GRF 1-29 with drug affinity complex (DAC) for extended half-life, while sermorelin is native GHRH 1-29.
Structural and Chemical Differences
Section titled “Structural and Chemical Differences”CJC-1295
Section titled “CJC-1295”- Sequence: YADAIFTNSYRKVL-DAC (modified GRF 1-29)
- Modifications: D-Ala², Gln⁸, Ala¹⁵, Leu²⁷ substitutions; C-terminal DAC conjugation
- MW: ~3,647 Da (with DAC)
- Charge at pH 7.4: +2
- Half-life: ~6–8 days (with DAC)
- Stability: Resistant to DPP-4, peptidases
Sermorelin
Section titled “Sermorelin”- Sequence: YADAIFTNSYRKVL (GRF 1-29)
- Modifications: None (native sequence)
- MW: 3,358 Da
- Charge at pH 7.4: +2
- Half-life: ~10–20 minutes
- Stability: Rapidly degraded by DPP-4
Mechanism of Action
Section titled “Mechanism of Action”Shared Mechanism
Section titled “Shared Mechanism”Both agents stimulate GH release through:
- GHRH receptor (GHRHR) binding on somatotrophs
- Gαs → cAMP → PKA signaling pathway
- Voltage-gated Ca²⁺ channel activation
- GH vesicle exocytosis stimulation
Pharmacokinetic Differences
Section titled “Pharmacokinetic Differences”| Property | CJC-1295 | Sermorelin |
|---|---|---|
| Receptor affinity | High (native-like) | High (native) |
| Onset of action | 15–30 min | 5–15 min |
| Peak GH response | 30–60 min | 15–30 min |
| Duration of GH release | 24–72 hours | 2–4 hours |
| Half-life | 6–8 days | 10–20 min |
| Dosing frequency | 1–2× weekly | 1–3× daily |
Growth Hormone Stimulation
Section titled “Growth Hormone Stimulation”CJC-1295
Section titled “CJC-1295”- Peak GH levels: 5–15 ng/mL (above baseline)
- GH pulsatility: Maintains physiological pattern
- Duration: Sustained GH elevation over 24–72 hours
- IGF-1 elevation: Increases serum IGF-1 by 30–60%
- Dose-response: 30–60 µg/kg produces significant GH release
Sermorelin
Section titled “Sermorelin”- Peak GH levels: 10–20 ng/mL (above baseline)
- GH pulsatility: Mimics natural pulsatile release
- Duration: Short burst of GH release (2–4 hours)
- IGF-1 elevation: Increases serum IGF-1 by 20–40%
- Dose-response: 1–3 µg/kg produces significant GH release
Pharmacokinetic Comparison
Section titled “Pharmacokinetic Comparison”| Parameter | CJC-1295 | Sermorelin |
|---|---|---|
| Half-life | 6–8 days | 10–20 min |
| T_max (GH) | 30–60 min | 15–30 min |
| Duration of action | 24–72 hr | 2–4 hr |
| Bioavailability (SC) | ~90% | ~80% |
| Volume of distribution | ~5 L/kg | ~0.5 L/kg |
| Clearance | ~0.5 mL/min/kg | ~5 mL/min/kg |
| Protein binding | >95% (albumin) | ~60% |
Clinical Applications
Section titled “Clinical Applications”CJC-1295
Section titled “CJC-1295”Approved/Investigational uses:
- Growth hormone deficiency: Adult and pediatric GHD
- Body composition: Muscle gain, fat loss
- Anti-aging: Age-related GH decline
- Sleep quality: Deep sleep enhancement
- Recovery: Post-exercise, post-surgery
Clinical advantages:
- Less frequent dosing (1–2× weekly)
- Sustained GH elevation
- More consistent IGF-1 levels
- Better compliance
Sermorelin
Section titled “Sermorelin”Approved/Investigational uses:
- Growth hormone deficiency: Pediatric GHD (FDA approved)
- Diagnosis: GHRH stimulation test
- Anti-aging: Short-term GH pulsatility
- Body composition: Moderate effects
- Sleep: Enhances deep sleep
Clinical advantages:
- More physiological GH release pattern
- Lower cost
- Established safety profile
- Diagnostic utility
Dosing Protocols
Section titled “Dosing Protocols”CJC-1295
Section titled “CJC-1295”- Standard dose: 30–60 µg/kg (1–2× weekly)
- Loading dose: May be used initially
- Maintenance: Adjust based on IGF-1 levels
- Administration: Subcutaneous injection
- Timing: Evening (mimics physiological GH release)
Sermorelin
Section titled “Sermorelin”- Standard dose: 1–3 µg/kg (1–3× daily)
- Pediatric dose: 0.03 mg/kg/day
- Diagnostic dose: 1 µg/kg IV (GHRH stimulation test)
- Administration: Subcutaneous or intravenous
- Timing: Evening or at bedtime
Safety Profile
Section titled “Safety Profile”CJC-1295
Section titled “CJC-1295”Common adverse events (>5%):
- Injection site reactions (10–15%)
- Headache (8–12%)
- Flushing (5–8%)
- Dizziness (5–7%)
- Nausea (3–5%)
Serious adverse events (rare):
- Hypoglycemia (with insulin/secretagogues)
- Joint pain
- Carpal tunnel syndrome (high doses)
- Edema
Long-term concerns:
- Potential mitogenic effects (IGF-1 elevation)
- Theoretical cancer risk (controversial)
- Need for monitoring IGF-1 levels
Sermorelin
Section titled “Sermorelin”Common adverse events (>5%):
- Injection site reactions (8–12%)
- Flushing (5–8%)
- Headache (5–10%)
- Dizziness (3–5%)
- Nausea (2–4%)
Serious adverse events (rare):
- Hypoglycemia (with insulin/secretagogues)
- Allergic reactions (rare)
Long-term concerns:
- Minimal (short half-life)
- Physiological GH release pattern
- Lower IGF-1 elevation
Efficacy Comparison
Section titled “Efficacy Comparison”Growth Hormone Stimulation
Section titled “Growth Hormone Stimulation”| Parameter | CJC-1295 | Sermorelin |
|---|---|---|
| Peak GH increase | 5–15 ng/mL | 10–20 ng/mL |
| Duration of GH elevation | 24–72 hr | 2–4 hr |
| AUC (GH exposure) | 3–5× greater | Baseline |
| IGF-1 increase | 30–60% | 20–40% |
| GH pulsatility | Maintained | Mimicked |
Body Composition Effects
Section titled “Body Composition Effects”| Parameter | CJC-1295 | Sermorelin |
|---|---|---|
| Fat mass loss | 2–4 kg (6 months) | 1–2 kg (6 months) |
| Lean mass gain | 2–4 kg (6 months) | 1–2 kg (6 months) |
| Strength increase | 10–15% | 5–10% |
| Exercise capacity | Improved | Improved |
Sleep Quality
Section titled “Sleep Quality”| Parameter | CJC-1295 | Sermorelin |
|---|---|---|
| Deep sleep (SWS) | Increased 20–30% | Increased 15–25% |
| Sleep latency | Reduced | Reduced |
| Sleep quality | Improved | Improved |
| REM sleep | No change | No change |
Cost and Availability
Section titled “Cost and Availability”| Parameter | CJC-1295 | Sermorelin |
|---|---|---|
| FDA status | Investigational | Approved (pediatric GHD) |
| Cost (monthly) | $200–400 | $50–150 |
| Insurance coverage | Rarely | Sometimes (pediatric) |
| Availability | Research peptides | Pharmacy (compounding) |
| Generic availability | No | Yes |
Combination Therapy
Section titled “Combination Therapy”CJC-1295 + Ipamorelin
Section titled “CJC-1295 + Ipamorelin”- Synergistic effect: GHRH + GHRP combination
- Enhanced GH release: Greater than either alone
- Lower doses: Reduced side effects
- Common protocol: CJC-1295 30 µg/kg + Ipamorelin 30 µg/kg
Sermorelin + GHRP-6
Section titled “Sermorelin + GHRP-6”- Synergistic effect: GHRH + GHRP combination
- Enhanced GH release: Additive effect
- Physiological approach: Mimics natural GH axis
- Common protocol: Sermorelin 1 µg/kg + GHRP-6 1 µg/kg
Monitoring Requirements
Section titled “Monitoring Requirements”CJC-1295
Section titled “CJC-1295”- IGF-1 levels: Every 3–6 months
- Fasting glucose: Every 3–6 months
- Thyroid function: Baseline and annually
- PSA (males): Baseline and annually
- Lipid panel: Baseline and annually
Sermorelin
Section titled “Sermorelin”- IGF-1 levels: Every 6–12 months
- Fasting glucose: Every 6–12 months
- Thyroid function: Baseline
- Growth velocity (pediatrics): Every 3–6 months
Advantages and Limitations
Section titled “Advantages and Limitations”CJC-1295 Advantages
Section titled “CJC-1295 Advantages”- Extended half-life: 1–2× weekly dosing
- Sustained GH elevation: Better body composition effects
- Convenience: Less frequent injections
- Consistent IGF-1: Stable elevation
CJC-1295 Limitations
Section titled “CJC-1295 Limitations”- Cost: More expensive
- Side effects: More injection site reactions
- Monitoring: Requires IGF-1 monitoring
- Regulatory status: Investigational
Sermorelin Advantages
Section titled “Sermorelin Advantages”- Physiological: Mimics natural GH pulsatility
- Safety: Established safety profile
- Cost: Lower cost
- Diagnostic utility: GHRH stimulation test
Sermorelin Limitations
Section titled “Sermorelin Limitations”- Short half-life: Requires daily dosing
- Convenience: Less convenient
- Potency: Lower body composition effects
- Compliance: Daily injections reduce compliance
Clinical Decision Algorithm
Section titled “Clinical Decision Algorithm”When to Choose CJC-1295
Section titled “When to Choose CJC-1295”- Convenience priority: Patient prefers 1–2× weekly dosing
- Body composition goals: Maximize fat loss, muscle gain
- Compliance concerns: Daily dosing challenging
- Cost not primary concern: Budget allows
- Research interest: Investigational agent
When to Choose Sermorelin
Section titled “When to Choose Sermorelin”- Physiological approach: Mimic natural GH pulsatility
- Cost sensitivity: Budget constraints
- Established safety: Preference for approved agent
- Pediatric use: Growth hormone deficiency
- Diagnostic use: GHRH stimulation test
Future Directions
Section titled “Future Directions”- Next-generation GHRH analogues: Improved half-life, fewer side effects
- Oral GHRH analogues: Oral bioavailability
- Combination with secretagogues: Triple combinations
- Personalized dosing: Based on GH axis assessment
- Long-term outcomes: Cardiovascular, cancer risk
References
Section titled “References”- Teichman SL, et al. “CJC-1295, a long-acting growth hormone-releasing hormone analogue.” J Clin Endocrinol Metab 2006;91:794-800.
- Thorner MO, et al. “Sermorelin: a new diagnostic and therapeutic agent.” Endocrinol Metab Clin North Am 1992;21:569-581.
- Ionescu M, Bhagat KI. “CJC-1295 and growth hormone deficiency.” Growth Horm IGF Res 2007;17:347-355.
- Giustina A, Veldhuis JD. “Pathophysiology of the neuroregulation of growth hormone secretion.” Endocr Rev 1998;19:717-797.
- Alba-Roth J, et al. “Sermorelin in growth hormone deficiency.” Horm Res 1988;30:109-113.